What is the recommendation for the use of DOACs in patients with antiphospholipid syndrome?
Based on current evidence, it is not recommended to use DOACs in general and, specifically, rivaroxaban for antiphospholipid syndrome until other ongoing trials such as ASTRO-APS (Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid clarify whether the increased risk of thrombosis with DOACs is a class effect versus an individual drug effect.